Drug intelligence / Profile preview

staphylococcal enterotoxin C

Development stage
Discontinued
Modality
Plant Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration
Oral, Inhalation, Topical, Intravaginal, Intramuscular, Subcutaneous
01

Overview

Staphylococcal enterotoxin C (SEC) is a protein exotoxin produced by *Staphylococcus aureus* and is one of the most common causes of foodborne intoxications (staphylococcal food poisoning). It acts as both an emetic toxin and a superantigen. As a superantigen, it binds to major histocompatibility complex class II molecule on antigen-presenting cells and activates large numbers of CD4+ T cells, leading to massive cytokine release and inflammatory responses. This mechanism underlies its role in diseases such as toxic shock syndrome and gastrointestinal inflammation. There are at least four subtypes (SEC-1 to SEC-4), each associated with different disease profiles; for example, some are linked to menstrual toxic shock syndrome while others are associated with severe pneumonia or mastitis[1][2][5]. The toxin’s emetic activity is attributed to its structural features—specifically a disulfide loop critical for inducing vomiting[1]. In addition to human disease, it plays an important role in animal health (notably bovine mastitis)[4]. Mutated or detoxified forms have been studied as potential vaccine candidates against toxic shock syndrome[8].

Other names
staphylococcal enterotoxin Centerotoxin C
02

Targets

MHC II (Major histocompatibility complex class II receptor)TRBV (T-cell receptor beta variable chain family)CD4 (T lymphocyte surface antigen)

Beyond the preview

Go deeper on staphylococcal enterotoxin C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on staphylococcal enterotoxin C.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call